Your browser doesn't support javascript.
loading
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF.
Butt, Jawad H; Docherty, Kieran F; Jhund, Pardeep S; de Boer, Rudolf A; Böhm, Michael; Desai, Akshay S; Howlett, Jonathan G; Inzucchi, Silvio E; Kosiborod, Mikhail N; Martinez, Felipe A; Nicolau, Jose C; Petrie, Mark C; Ponikowski, Piotr; Bengtsson, Olof; Langkilde, Anna Maria; Schou, Morten; Sjöstrand, Mikaela; Solomon, Scott D; Sabatine, Marc S; McMurray, John J V; Køber, Lars.
Affiliation
  • Butt JH; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Docherty KF; Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
  • Jhund PS; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • de Boer RA; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Böhm M; Department of Cardiology, University Medical Center and University of Groningen, Groningen, The Netherlands.
  • Desai AS; Department of Internal Medicine III, Saarland University Hospital, Saarland University, Homburg, Germany.
  • Howlett JG; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Inzucchi SE; Cumming School of Medicine and Libin Cardiovascular Institute, University of Calgary, Calgary, Canada.
  • Kosiborod MN; Section of Endocrinology, Yale School of Medicine, New Haven, CT, USA.
  • Martinez FA; Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City; The George Institute for Global Health, University of New South Wales, Sydney, Australia.
  • Nicolau JC; Universidad Nacional de Córdoba, Córdoba, Argentina.
  • Petrie MC; Instituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  • Ponikowski P; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Bengtsson O; Center for Heart Diseases, University Hospital, Wroclaw Medical University, Wroclaw, Poland.
  • Langkilde AM; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Schou M; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Sjöstrand M; Department of Cardiology, Herlev-Gentofte University Hospital, Herlev, Denmark.
  • Solomon SD; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Sabatine MS; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • McMurray JJV; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Køber L; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Eur J Heart Fail ; 24(3): 513-525, 2022 03.
Article in En | MEDLINE | ID: mdl-34766424
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Heart Failure Type of study: Clinical_trials Limits: Humans Language: En Journal: Eur J Heart Fail Journal subject: CARDIOLOGIA Year: 2022 Document type: Article Affiliation country: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Heart Failure Type of study: Clinical_trials Limits: Humans Language: En Journal: Eur J Heart Fail Journal subject: CARDIOLOGIA Year: 2022 Document type: Article Affiliation country: Reino Unido